Drug Discovery & DDS– category –
-
Drug Discovery & DDS Weekly Report August 16, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 16, 2026 (PDF) — Download Weekly Report August 16, 2026 (PDF) — DownloadDownload 🎙 Podcast August 16, ... -
Xcellon Biologics Acquires NextCure GMP Facility, Establishes End-to-End CRDMO for Next-Gen Bioconjugates, Streamlining Development from Discovery to Clinical Supply
Outsourced Pharma USA Overview Xcellon Biologics has acquired a GMP manufacturing facility from NextCure, transforming into an end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) for next-generation bioconju... -
Korro Bio Accelerates RNA Editing Platform into Clinic with First-in-Human Trial for Hyperammonemia and Designation of AATD Candidate
GlobeNewswire (via Korro Bio, Inc.) USA Overview Korro Bio has announced plans to initiate first-in-human clinical trials for its hyperammonemia treatment candidate, KRRO-121, in late 2026. Concurrently, the company designated KRRO-111 a... -
ProQR Therapeutics Marks Landmark: Axiomer RNA Editing Platform Achieves First Clinical Validation for Cholestatic Liver Disease Therapy
Quartr Sweden Overview ProQR Therapeutics has reported the first clinical validation of its proprietary Axiomer RNA editing platform, achieved through Phase 1 target engagement data for AX-0810. This candidate demonstrated modulation of ... -
Rice University Engineers Harness Electrostatic Charge for Weeks-Long Controlled Peptide Release, Revolutionizing Regenerative Medicine
Rice University USA Overview Engineers at Rice University have developed a novel strategy to precisely control the release of therapeutic peptides from gelatin-based materials. By adjusting the peptide's electrical charge, the team signi... -
Beijing Designates Xtalpi and Gan & Lee’s AI Peptide Delivery Lab as Key National Facility for Oral Drug Innovation
Insight, China's Pharmaceutical Industry China Overview The AI Peptide Delivery Lab, a joint venture by Xtalpi and Gan & Lee Pharmaceuticals, has been officially designated a Beijing Key Laboratory, recognizing its cutting-edge R&... -
Fatal Adverse Event Halts HuidaGene’s First-in-Human CRISPR Gene Therapy Trial for DMD
HuidaGene Therapeutics China Overview HuidaGene Therapeutics has reported a fatal serious adverse event (SAE) in the HG302-01 first-in-human trial of its investigational CRISPR-based gene-editing therapy, HG302, for Duchenne muscular dys... -
Peptide Therapeutics: Charting a Course to Oral Delivery Amidst a Surge in FDA Approvals
Stanford Medicine USA Overview The FDA has approved nearly 100 peptide therapeutics for conditions ranging from diabetes to multiple sclerosis, yet most require injection due to their susceptibility to gastrointestinal degradation. A rec... -
Lonza Capsugel Pioneers Dual-Layer Strategy for Oral GLP-1 Delivery, Shielding Peptides from Enzymatic Attack
Capsugel (Lonza) Switzerland Overview Lonza Capsugel has engineered a novel dual-layer protection strategy to enable oral delivery of GLP-1 peptides, circumventing the critical challenge of enzymatic degradation within the gastrointestin... -
Alector Advances ‘Brain Carrier’ Platform: Optimizing Brain Drug Delivery via Transferrin Receptor Targeting with Enhanced Safety
Alector USA Overview Alector recently announced significant progress with its proprietary Alector Brain Carrier (ABC) blood-brain barrier (BBB) platform, designed to substantially enhance the delivery of therapeutic agents to the brain. ...
